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Background: Anxiety and depression are common in cardiac rehabilitation (CR) patients.
However, CR programs which incorporate psychological techniques achieve modest
reductions in emotional distress. More efficacious interventions that can be easily
integrated within services are required. A promising alternative to current psychological
interventions is metacognitive therapy (MCT). The aim was to evaluate the acceptability
and feasibility of delivering Group-MCT to CR patients experiencing symptoms of anxiety
and depression.
Method and Results: Fifty-two CR patients with elevated anxiety and/or depression
were recruited to a single-blind randomized feasibility trial across three UK National Health
Service Trusts and randomized to usual CR or usual CR plus six weekly sessions of
group-MCT. Acceptability and feasibility of adding group-MCT to CR was based on
recruitment rates, withdrawal, and drop-out by the primary end-point of 4 months;
number of MCT and CR sessions attended; completion of follow-up questionnaires;
and ability of the outcome measures to discriminate between patients. The study was also
used to re-estimate the required sample size for a full-scale trial. We also examined the
extent by which non-specialists adhered to the Group-MCT protocol. Group-MCT was
found to be feasible and acceptable for CR patients with anxiety and depression.
Recruitment and retention of participants was high, and attendance rates at CR were
similar for both groups.
Frontiers in Psychiatry | www.frontiersin.org June 2020 | Volume 11 | Article 5821
Edited by:
Richard Porter,
University of Otago,
New Zealand
Reviewed by:
Jennifer Jordan,
University of Otago,
Christchurch, New Zealand
Lee Kannis-Dymand,
University of the Sunshine
Coast, Australia
*Correspondence:
Adrian Wells
Adrian.wells@manchester.ac.uk
Specialty section:
This article was submitted to
Mood and Anxiety Disorders,
a section of the journal
Frontiers in Psychiatry
Received: 13 March 2020
Accepted: 05 June 2020
Published: 30 June 2020
Citation:
Wells A, Reeves D, Heal C, Fisher P,
Davies L, Heagerty A, Doherty P and
Capobianco L (2020) Establishing the
Feasibility of Group Metacognitive
Therapy for Anxiety and Depression in
Cardiac Rehabilitation: A Single-Blind
Randomized Pilot Study.
Front. Psychiatry 11:582.
doi: 10.3389/fpsyt.2020.00582
CLINICAL TRIAL
published: 30 June 2020
doi: 10.3389/fpsyt.2020.00582
Conclusion: The results suggest the addition of MCT to CR did not have a negative
impact on retention and support a full-scale trial of Group-MCT for cardiac patients.
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INTRODUCTION
Heart and circulatory disease is associated with approximately
170,000 deaths each year in the UK (1). However, survival rates
are improving, and approximately 7.4 million people are living
with heart and circulatory disease in the UK (1). Rehabilitation
following a cardiac event is vital for improving health outcomes,
quality of life, and survival. The UK Department of Health,
National Institute for Health and Care Excellence (NICE)
guidelines (CG172, CG94, and NG106), and the British
Association for Cardiovascular Prevention and Rehabilitation
(BACPR) recommend that cardiac rehabilitation (CR) programs
are offered to all eligible patients (2–4).
Modern CR programs are comprised of exercise training,
psychosocial support, risk factor management, and education
underpinned by a behavior change approach (2). CR is cost-
effective (5, 6), reduces mortality and morbidity (5, 7), and
increases quality of life (5, 8). However, improvement of
anxiety and depression in cardiac rehabilitation is limited.
Anxiety and depression are highly prevalent among CR
patients, with 27.6% of CR patients experiencing clinically
significant anxiety and 19% experiencing clinically significant
depression (9). Furthermore, elevated anxiety and depression
have been associated with decreased medication adherence,
decreased CR attendance (10), decreased quality of life,
increased risk of reoccurrence of cardiac related events, and a
higher rate of mortality, leading to greater service use and
increased NHS costs (11, 12).
Combined with the low rates of provision of psychological
treatment, those treatments that have been evaluated appear to
have limited efficacy. Current interventions for anxiety and
depression for patients with a physical illness often focus on
cognitive behavioral therapy (CBT). A recent Cochrane
systematic review and meta-analysis evaluated psychological
interventions in coronary heart disease in comparison to
treatment as usual, and included 35 studies. Common
components of psychological interventions included relaxation
techniques, self-awareness and self-monitoring, emotional
support/client-led discussion, and cognitive challenging/
cognitive restructuring. At post-treatment interventions were
associated with a between group effect size of 0.27 (Cohen's d)
for symptoms of depression, with similar results for symptoms of
anxiety (Cohen's d = 0.24) (13). This is in line with previous
studies that highlight the limited efficacy of psychological
interventions in cardiac patients (14, 15). It is evident that
more effective interventions that can be easily integrated within
services are required.
Metacognitive therapy (MCT) (16), is a transdiagnostic
therapy found to be efficacious in mental health settings [see
(17)]. MCT might be well suited to the psychological needs of
cardiac patients because it does not depend on challenging the
validity of negative thoughts and beliefs which can be realistic
in people suffering from chronic and potentially life-
threatening conditions. MCT is based on the self-regulatory
executive function model (S-REF model) (18, 19) of
psychological disorders. In the S-REF model, anxiety,
depression, and adjustment difficulties are maintained by the
activation of a maladaptive thinking style called the cognitive
attentional syndrome (CAS). The CAS is characterized by
worrying, rumination, inflexible attention to threat, and
maladaptive coping strategies. The CAS is driven by
underlying metacognitive beliefs, which can be differentiated
into positive and negative subtypes. Positive metacognitive
beliefs concern the usefulness of worry (e.g. “worrying helps
to detect problems before it is too late”) while negative
metacognitive beliefs concern uncontrollability (e.g. “I
cannot stop worrying about the future”) and dangerousness
of worry (e.g. “worrying will cause a heart attack”).
Normann and Morina (17) conducted a systematic review
and meta-analysis of the efficacy of metacognitive therapy for
anxiety and depression and found that MCT demonstrated a
large between group effect size at post treatment (Hedges' g =
2.06) when compared to a waitlist control condition. When MCT
was compared to cognitive and behavioral interventions MCT
also demonstrated large effect sizes favoring MCT at post
treatment (Hedges' g = 0.69). MCT has also shown promising
results when delivered using a group format in mental health
settings. To date there have been nine studies evaluating Group-
MCT across various disorders including obsessive compulsive
disorder (20, 21), generalized anxiety disorder (22–24),
depression (25, 26), and in mixed disorder groups (27, 28). No
studies to date have compared Group-MCT with individual
MCT, but a preliminary comparison of Group-MCT with
group mindfulness based stress reduction in mixed anxiety and
depression groups found that both were feasible and acceptable,
with large within-subject effects (27). In physical health
conditions MCT has primarily been evaluated in cancer, with
promising pilot results (29–31).
While positive outcomes for MCT within mental health
settings are rapidly gaining support, accelerated research efforts
are needed in the application to treating psychological distress
symptoms in physical health. As such the aims of the current
study were to evaluate the acceptability and feasibility of
delivering group metacognitive therapy within cardiac
rehabilitation services, the present study was intended to serve
as a feasibility for a subsequent definitive trial [trial protocol:
(32)]. Our research questions were: (1) What are the recruitment
and retention rates? (2) Do therapists adhere to the treatment
protocol? (3) What proportion of the treatment (i.e. CR and
Group-MCT) is completed by patients? (4) What is the rate of
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return of measures and the variability in scores for primary and
secondary outcomes? (5) Are there any adverse events or serious
adverse events in the intervention group? (6) What is the sample
size required for a full-scale trial?
METHODS
Design
The PATHWAY Group-MCT pilot feasibility study is a
multicenter randomized controlled trial with 4- and 12-
month follow-up comparing Group-MCT plus usual cardiac
rehabilitation (intervention) versus usual cardiac rehabilitation
(control). The study served as an internal pilot to the full-scale
RCT (32). The study was approved by the National Research
Ethics Service of the UK's National Health Service (ref 14/NW/
0163) and registered with a clinical trial data base (ISRCTN
reference: ISRCTN74643496).
Patients referred to CR programs in the UK are routinely sent
a National Audit of Cardiac Rehabilitation assessment pack (9),
which includes the Hospital Anxiety and Depression Scale
(HADS) (33). Participants were recruited from three NHS
cardiac rehabilitation services in the North West of England
(University Hospital of South Manchester NHS Foundation
Trust, Central Manchester University Hospitals NHS
Foundation Trust, and East Cheshire NHS Trust). At the initial
assessment appointment, CR staff reviewed each patient's medical
notes for inclusion and exclusion criteria, initially screening for
those who scored eight or above on either the HADS anxiety and
or depression subscale, indicative of at least “mild”
symptomatology. In addition, participants had to meet the
Department of Health and/or British Association for Cardiac
Prevention and Rehabilitation CR eligibility criteria, be aged 18
years or older, and have a competent level of English language
(able to read, understand, and complete questionnaires in
English). Patients who were eligible for the trial were invited to
take part. Inclusion and exclusion criteria are provided in further
detail in Wells et al. (32). Eligible participants were contacted by
research assistants and participants were provided with further
information on the trial and had the opportunity to ask questions
about participation in the study. Participants were consented
face-to-face with a research assistant either at the patient's home
or at the site of their CR. Research assistants taking consent, the
chief investigator and trial statisticians were blind to each
patient's treatment allocation. Data monitoring, quality, and
handling were undertaken by the Manchester Clinical Trials
unit and project oversight was by an independent trial steering
committee. The trial has been reported in line with CONSORT
statement for the reporting of pilot and feasibility randomized
controlled trials (34).
Patient and Public Involvement
Patient and public involvement (PPI) has been extensively involved
throughout the course of the study. PPI service users were first
involved in grant development and commissioning of the research
project. After which, PPI service users were subsequently involved
in participant recruitment and ensuring that the number and
length of outcome measures selected did not overburden
participants, as well as aiding in recruitment and retention of
participants. Specifically, PPI service users aided in co-producing a
newsletter sent out to patients following 4-month follow-up to
remind patients of upcoming follow-up questionnaires and
updating participants about the study. PPI service users have also
aided in co-producing a dissemination plan and aiding in
dissemination of research findings.
Participants
The Consort diagram indicating patient flow is depicted in
Figure 1. Fifty-two eligible patients were randomized to either
usual cardiac rehabilitation (control) or to usual cardiac
rehabilitation plus group metacognitive therapy (intervention).
Randomization and Sample Size
Following informed consent, patients were randomly allocated to
a trial condition in a 1:1 ratio using a minimization algorithm
that incorporated a random component, in order to maximize
balance between the two arms on sex distribution, HADS anxiety
and depression scores, and hospital site. Table 1 provides a
summary of randomization variables by group. Randomization
was conducted via a telephone link to the Manchester University
Clinical Trial Unit (Manchester CTU).
The target sample size was originally 50 patients (25 per arm),
determined as sufficient to evaluate recruitment and retention
rates for a full-scale trial as well as rates of completion of the
intervention. This sample is also adequate for estimation of
variability in outcome measures for which samples of 40 are
considered sufficient (35). However, as a consequence of parallel
recruitment across sites, 52 patients had consented by the end of
the recruitment period and were included in the sample. Patterns
of participant sex and HADS subscale scores resulted in 23 of
these being allocated by computer to the intervention group and
29 to the controls. Sample characteristics are in Table 2.
Treatment
Treatment as Usual (TAU; Control)
Treatment as usual was the CR program delivered at each study
site in hospital and community settings. CR programs are
comprised of an exercise component and an educational
component. Both components are provided in group sessions
over 8 to 10 weeks, of 45 to 60 min. The therapist-to-patient ratio
in TAU exercise sessions is 1:5 for low- and moderate-risk
patients and 1:3 for high-risk patients. In addition to exercise
classes, educational seminars are delivered that focus on a variety
of topics including lifestyle and medical risk factor management.
TAU educational sessions varied by site and the extent of
psychological components also varied. While all sites delivered
sessions on relaxation which focused on breathing techniques
and progressive muscle relaxation, the content of sessions on
stress management differed. For example, two sites incorporated
cognitive therapy methods (i.e. challenging negative thoughts,
worry decision tree), while one site delivered psychoeducational
information on stress. In addition, one site offered a 4-week
stress management course as part of CR which included
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generating and sharing a case formulation based on Greenberger
and Padesky (36), mindfulness techniques, and individual
counseling with an occupational therapist.
Group-MCT Plus Treatment as Usual (Group-MCT;
Intervention)
Group-MCT was delivered in addition to usual CR. Group-MCT
was most often delivered on a different day to participants' CR
sessions, and only four intervention patients attended CR and
Group-MCT on the same day. Group-MCT was delivered in six
sessions of 60- to 90-min duration and followed a treatmentmanual
(37). Sessions focused on deriving a case formulation and
socialization, practicing the Spatial Attentional Control Exercise
(SpACE), detached mindfulness (DM), worry and rumination
postponement, challenging metacognitive beliefs concerning the
uncontrollability and danger of worrying and rumination, and
developing a “helpful behaviors” plan. The manual contains
techniques that help patients to change the type of relationship
that they have with their negative thoughts, allowing them to step
back and not engage in worry and/or rumination. One of the
techniques, SpACE, is a brief auditory exercise consisting of
instructions to allocate attention in different ways to discover
control over thinking while inhibiting responses to spontaneous
negative thoughts and prolonged attention capture by distractions.
The technique is designed to increase mental flexibility so that
negative thoughts and memories can be de-coupled from repetitive
negative thinking. DM is a technique used in Group-MCT in which
the patient learns to relate to thoughts and disengage from
unhelpful coping strategies. Patients were asked to practice
SpACE twice a day for homework and to practice applying DM
to negative thoughts. SpACE practice was recorded in a personal
diary and homework was reviewed at the start of each session with
discussions around successes and difficulties experienced. However,
data on practice were captured for analysis purposes.
Therapists
Group-MCT was delivered by CR staff who had received a basic
training in implementing the treatment manual. There were seven
therapists, two therapists per site except one site where three
therapists were trained. Therapists included occupational
therapists, physical therapists, and CR nurses. Therapists
completed a 2-day workshop delivered by the developer of MCT
(AW). Training included didactic teaching, role play, discussion,
and studying the treatment manual. In addition, therapists
delivered the intervention to a pilot group of volunteers along
with an additional 1-day workshop, which focused on enhancing
the initial skills. Therapists received ongoing supervision on an
occasional basis, while delivering the intervention.
FIGURE 1 | CONSORT flow diagram of patient recruitment.
TABLE 1 | Sample characteristics by Randomization Variable per Group.
Arm HADS Anxiety
≥ 8
HADS Depres-
sion ≥ 8
HADS Anxiety and
Depression ≥ 8
Male Female Male Female Male Female
TAU 6 3 2 2 9 7
TAU + Group-MCT 5 2 2 0 8 6
TAU, treatment as usual; MCT, metacognitive therapy; HADS, Hospital Anxiety and
Depression Scale.
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Measures
Outcome Measures
Hospital Anxiety and Depression Scale (HADS)
The Hospital Anxiety and Depression Scale [HADS; Zigmond
and Snaith (33)] was specified as the primary outcome for the
pilot trial and subsequent main RCT and is a 14-item measure
that assesses symptoms of anxiety and depression, where items
are scored on a 4-point Likert scale (0 to 3). The scale generates
two subscale scores (anxiety and depression) and a total score.
The total score was the pre-specified primary outcome measure.
The HADS total score has demonstrated good internal
consistency with Cronbach's alpha for the total score in cardiac
patients ranging from 0.85 to 0.89 (38, 39).
Impact of Events Scale-Revised (IES-R)
The Impact of Event Scale-Revised [IES-R; Weiss and Marmar (40)]
is a 22-item scale assessing symptoms of post-traumatic stress
disorder across three subscales, intrusions, avoidance, and
hyperarousal, plus a single total score. Each item is rated from 0
(not at all) to 4 (extremely) based on how distressing the item has
been in the past week with respect to their cardiac event. The scale
has shown high internal consistency across all three subscales:
intrusion Cronbach's alpha = 0.87 to 0.94; avoidance Cronbach's
alpha = 9.84 to 0.87; hyperarousal Cronbach's alpha = 0.79 to 0.91
(31–33); total Cronbach's alpha = 0.95 (41). The subscales also
demonstrate moderate to high inter-correlations (rs = 0.52–0.87) (41,
42). We pre-specified the total score as the outcome for this study.
Metacognitions Questionnaire-30 (MCQ-30)
The Metacognition Questionnaire-30 [MCQ-30; Wells and
Cartwright-Hatton (43)] is a 30 item measure that assesses
metacognitive beliefs across five subscales: (1) positive
metacognitive beliefs, (2) negative metacognitive beliefs
regarding uncontrollability and danger, (3) cognitive confidence,
(4) cognitive self-consciousness, and (5) need to control thoughts.
Items are scored on a four-point Likert scale (do not agree to agree
very much), whereby higher scores indicate greater maladaptive
metacognitive beliefs. A total score is also derived and was used as
the outcome measure for this study. The MCQ-30 possesses good
internal consistency (Cronbach's alphas 0.72 to 0.93 for individual
subscales) (43, 44).
Cognitive Attentional Syndrome-1 Revised (CAS-1R)
The Cognitive Attentional Syndrome-1 Revised [CAS1-R; Wells
(45)] is a 10-item measure that assesses different aspects of the CAS
across three subscales: coping strategies, positive metacognitive
beliefs, and negative metacognitive beliefs. The measure was
modified from the original CAS-1 (16) for use in PATHWAY.
Items are rated on an 11-point Likert scale ranging from 0 (none of
the time/not at all true) to 100 (all of the time/completely certain
this is true), whereby higher scores indicate greater use of
maladaptive coping strategies or maladaptive metacognitive
beliefs. The psychometric properties of the CAS-1R have been
evaluated in cardiac patients (46). The measure demonstrates
acceptable internal consistency for two subscales: coping strategies
(Cronbach's alpha = 0.88) and negative metacognitive beliefs
(Cronbach's alpha = 0.65); however, internal consistency was low
for the positive metacognitive beliefs subscale (Cronbach's alpha =
0.58). The scale demonstrates good construct validity and is a
significant predictor of anxiety and depression in cardiac patients.
EQ-5D-5L
The EQ-5D-5L [EuroQol (47)] describes and values health across
five dimensions: mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression (48). Response items range
TABLE 2 | Baseline Demographic and Clinical Characteristics.
Demographic factors Entire sample (N = 52)
n (%)
Sex
Male 33 (63.5%)
Female 19 (36.5%)
Ethnicity
Any white 43 (82.7%)
All other categories 8 (15.4%)
Psychological therapies for anxiety or depression
In the past 18 (34.6%)
Never 34 (65.4%)
Age 58 (9.6)
Employment:
Economically active 18 (34.6%)
Unemployed 8 (15.4%)
Retired 16 (30.8%)
All other 10 (19.2%)
Educational qualification
None 16 (30.8%)
School/vocational 22 (42.3%)
Diploma/degree 14 (26.9%)
Civil status:
In relationship 26 (50.0%)
Separated 18 (34.6%)
Single 8 (15.4%)
Smoking status
Never smoked 16 (30.8%)
Ex-smoker 31 (59.6%)
Current smoker 5 (9.6%)
Alcohol units per month
None 21 (40.4%)
1 to 19 17 (32.7%)
20 to 49 7 (13.5%)
50 or more 7 (13.5%)
Age at first cardiovascular event
Under 45 years 5 (9.6%)
45 to 54 years 21 (40.4%)
55 years and older 25 (48.1%)
Number of cardiac events
None 38 (73.1%)
1 7 (13.5%)
2 or more 7 (13.5%)
BMI
Underweight/normal 14 (26.9%)
Overweight 21 (40.4%)
Obese 15 (28.9%)
Number of comorbidities [mean (SD)] 5.1 (2.1)
Outcomes Mean (SD)
HADS total 17.5 (5.7)
HADS anxiety 10.1 (3.6)
HADS depression 7.4 (3.5)
Impact of Event Scale-Revised (IESR) 32.6 (19.2)
Metacognitions Questionnaire 30 (MCQ-30) 62.3 (15.1)
EQ-5D-5L Utility 0.60 (0.3)
EQ-5D VAS 61.5 (18.5)
CAS-1R 394.1 (185.2)
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from no problem to extreme problem. The EQ-5D-5L can be
calculated as a total score and also converted to a utility score. In
addition, participants rate their overall health using a visual
analog scale (VAS), which ranges from 0 (worst health
imaginable) to 100 (best health imaginable).
Statistical Analysis
Statistical analysis was principally descriptive. We assessed the
acceptability of adding Group-MCT to usual CR in terms of rates
of recruitment into the study (number agreeing to participate out
of those approached, and number recruited per month),
withdrawal or drop-out by the primary endpoint of 4 months
(attrition rate), and numbers of MCT and CR sessions attended.
The feasibility of conducting a full trial was assessed with
regard to completion of follow-up questionnaires (proportions of
missing values, both overall and within trial arms), ability of the
outcome measures to discriminate between patients (range of
scores; floor or ceiling effects), and re-estimation of the required
sample size based on the findings of this study (number of
recruited patients required to detect an effect size of 0.4 on HADS
total score at 80% power, controlling for baseline scores and
allowing for attrition and clustering of patients within therapy
groups). We examined therapist level of adherence to the
treatment protocol since these individuals were non-mental
health specialists without prior experience of delivering
psychological treatments. An adherence checklist was used for
this purpose, whereby therapists indicated the aspects of the
protocol implemented in each session, if they had been missed
and if so why. For example, in the first session adherence items
included completing the case formulation, socializing patients to
the model, practicing SpACE, and assigning homework.
Consistently evaluated elements in each session included
reviewing and assigning homework and practicing SpACE. A
total adherence score was created for each session by summing
the total number of elements completed in session.
RESULTS
Participants
52 participants (19 female, 33 male) took part in the study.
Patients had a mean age of 58.10 (SD = 9.61, range: 38–79).
Participants ethnic origin was primarily white (82.7%); however,
eight participants identified as the following ethnic origins: Asian
Bangladeshi (n = 1), Asian Indian (n = 1), Asian Pakistani (n =
1), Any other Asian background (n = 1), Black Caribbean (n = 3),
and any other Black background (n = 1). Patients had a range of
heart conditions including: acute coronary syndrome (n = 31),
revascularization (n = 26), heart failure (n = 9), angina (n = 3),
implantation of cardioverter defibrillator (n = 1), heart valve
repair/replacement (n = 8), and adult congenital heart disease
(n = 2). At initial assessment, the mean anxiety score was 10.02
(SD = 3.27), and the mean depression score was 8.48 (SD = 3.13).
30 patients met criteria for both anxiety and depression, 16
patients met criteria for anxiety only, and 6 met criteria for
depression only.
Acceptability
Patients and therapists were asked about the acceptability of the
treatment in a separate qualitative study that will be reported in
detail elsewhere. The qualitative reports suggested that both
patients and therapists found the treatment to be logical and
appropriate for the problems being addressed.
Feasibility Assessment
Recruitment
Participant recruitment took place over 8 months across three
CR services in the North West of England. During this time 696
patients were referred to CR programs, of which 203 (29.2%) had
a score of 8 or more on either or both HADS subscales. 137
patients met the study eligibility criteria, and 119 of these were
provided with further information on the study. Of the 119, 14
started CR before they could be offered the trial (making them
ineligible), 21 were missed (i.e. not screened for eligibility), while
another 32 declined to participate. The remaining 52 (38% of
those eligible to take part) were consented and randomized into
the study. As such, over 8 months the rate of recruitment was
approximately 6.5 patients consented and randomized
per month.
Outcome Measures
To maintain the masking of the trial statistician (necessary for
the inclusion of this data in the definitive RCT) the analyses of
the outcome measures in the current study has been conducted
on the full sample only. There was no missing data on any
outcome measure at baseline. Table 3 provides a summary of the
TABLE 3 | Descriptive Statistics on Outcome Measures at Baseline.
Outcome measure Sample
Size
%
Missing
Median (inter-
quartile range)
Minimum and maximum
observed scores
Minimum possible score
(% scoring minimum)
Maximum possible score
(% scoring maximum)
Hospital Anxiety and Depression
Scale (total score)
52 0 17 (13.5–22) 1, 28 0 (0%) 42 (0%)
Impact of Event Scale-Revised
(total)
52 0 30.5 (18–45) 1, 85 0 (0%) 88 (0%)
Metacognitions Questionnaire 30
(total)
52 0 60 (52.5–72.6) 32, 97 30 (0%) 120 (0%)
EQ-5D-5L (total) 52 0 10 (8–14) 5, 19 5 (7.7) 25 (0%)
EQ-5D-5L utility score 52 0 0.66 (0.45–0.80) −0.065, 1 −0.594 (0%) 1 (7.7%)
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descriptive statistics for each outcome measure and Figure 2
provides a histogram for each. All questionnaires demonstrated a
good range of observed scores, covering the majority of the
possible score range, and with little in the way of floor or ceiling
effects. We note that HADS scores at baseline could (and did) go
below the minimum of eight that applied at the time eligibility
was assessed.
Treatment Attendance and Retention
Usual Care Condition
CR exercise sessions were well attended, with a median of six
sessions attended and 58.6% of patients attending at least
six sessions.
Intervention Condition
Patients in Group-MCT had a high attendance rate at CR
exercise sessions, with a median of six sessions attended and
52.2% of patients attending at least six sessions. Figure 3
summarizes the number of CR exercise sessions attended
by group.
Overall, attendance at Group-MCT was high, with 13 patients
(56.5%) attending at least four out of six sessions of which 11
(47.8%) attended all six. However, five patients (21.7%) did not
attend any sessions and five (21.7%) attended only one or two.
Four-Month Follow-Up
At 4-month follow-up 72.4% and 69.6% of control and
intervention group participants, respectively, returned follow-
up questionnaires.
Onecontrol groupparticipant formallywithdrew fromthe study
(3.5%), though this was immediately after randomization. Six
control group patients did not return questionnaires at follow-up
(20.7%), and one questionnaire was lost in the post (3.5%).
In comparison, four (17.4%) MCT-arm participants formally
withdrew from the study before 4-month follow-up. Reasons for
withdrawal included no longer having enough time to commit to
the study (n = 1), and no longer being interested in the study (n =
3). However, as only two additional MCT-arm patients failed to
return the 4-month follow-up the overall response was similar.
One questionnaire was lost in the post (4.4%).
FIGURE 2 | Outcome measure histograms.
FIGURE 3 | Number of cardiac rehabilitation exercise sessions attended by group.
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Group-MCT Adherence
We examined therapists' level of adherence to the treatment
protocol since the treatment was to be administered by non-
mental health specialists with no experience of delivering
psychological treatments. Therapists completed an adherence
checklist at the end of each session to indicate which aspects of
the session had been completed. Each site had two CR staff
members trained to deliver MCT, one site had three staff
members trained. Adherence to the protocol was high across
all three sites, with an average adherence rating across sites of
98.2%. Each site deviated from the protocol once; one site was
unable to practice SpACE in session three as the session over-
ran, while the remaining two sites both failed to review the
previous session's homework. One site failed to review the
homework in session five while the other site did not review
the homework in session six.
Eligibility Rates Before Baseline
There was an unavoidable delay between patients having their
initial CR assessment appointment and their subsequent
study baseline assessment. This period was on average 7.5
days (SD = 5.95), but went as high as 31 days; however, baseline
assessment was always completed prior to a patient's first
cardiac rehabilitation session (i.e. first exercise class). HADS
scores may change over this time, resulting in patients falling
below the eligibility criteria of 8 points on the anxiety or
depression subscale, and some may even spontaneously
experience full clinical recovery. To assess the extent of these
risks, we examined the change in HADS scores between initial
assessment and study baseline. Five patients (10%) made a
clinically significant improvement (i.e. made a seven-point
change on the HADS, calculated using (49), and two fell
below the cutoff score of 8 points. One patient was classified
as recovered (i.e. made a seven point change on the HADS and
crossed the cutoff score).
Sample Size Confirmation
The Pathway RCT is a superiority trial comprising of an initial
internal pilot followed by a main trial. The main trial was
designed to detect an effect size of 0.4 on HADS total and to
have 80% power not including the pilot sample. Under
assumptions of 25% attrition, a correlation of 0.5 between
baseline and follow-up outcome scores, mean therapy group
size of 5.75, and intra-cluster correlation coefficient (ICC) of
0.05, we estimated that a total recruitment sample of 230 patients
was required for the main trial. Should merging with the internal
pilot data prove feasible the final combined sample would be 280,
and the power 85%.
We revised this estimate on the basis of the results of this
internal pilot, which indicated an attrition rate of 35%, over-time
correlation of 0.5 (unchanged), mean group size of 3 and ICC of
0.05 (assumed). Since no substantial changes were made to the
trial procedures or instruments following the pilot, with the
consent of our steering committee and funders the decision was
taken to merge the pilot data with the main trial. Considering the
available time and resources, it was also decided to increase the
recruitment target to 332, to give the full study 90% power to
detect the desired 0.4 effect size.
Adverse Events
Adverse events and serious adverse events were monitored for
individuals in the intervention group. No adverse events were
reported. For further details on the safety reporting protocol for
the trial see (32).
DISCUSSION
Anxiety and depression are common in cardiac patients; however,
current psychological interventions for cardiac patients are limited
in efficacy, and as such novel psychological interventions are
needed. The current study evaluates the acceptability of Group-
MCT in cardiac patients and the feasibility of conducting a full
randomized trial to compare Group-MCT plus treatment as usual
to treatment as usual in this patient population.
Group-MCT was found to be both an acceptable and feasible
treatment to deliver to cardiac patients with anxiety and
depression. Recruitment and retention of participants to a
psychological trial is often difficult (50); however, the current
study successfully recruited to target. Recruitment rates were in
line with previous studies evaluating psychological interventions
within CR patients, whereby approximately 35% of eligible
patients agreed to take part in research (51). The HADS scores
of participants in the study were also similar to those obtained
in routine practice in the UK (52), which supports the
generalizability of the study to clinical settings. Although the
study did recruit to target there were challenges with recruitment,
for example, some patients were not screened for eligibility due to
limited CR staff or time to complete eligibility questionnaires. As
such, future studies should consider providing additional support
to CR staff during assessment clinics to assist with screening
patients for eligibility. Reasons for not taking part in the trial
included not having the time to commit to the study, returning to
work, and not being interested in the study. Interestingly, one
patient noted that despite scoring high on the HADS they did not
feel as though they were anxious or depressed and therefore did
not feel as though the research study was suitable for them.
Completion rates of CR were high at 75%, which is in line
with The National Audit of Cardiac Rehabilitation Annual
report, which highlights that nationally in the UK 77% of
patients complete CR (9). Completion of CR did not differ by
group or by site, suggesting that the addition of Group-MCT
does not impact on patient willingness to attend CR. Attendance
at Group-MCT was moderate to good, with more than half of all
patients attending at least four out of six sessions of Group-MCT,
and most of these attending all six. We consider attendance at a
minimum of four sessions to represent sufficient exposure to
benefit appreciatively from the intervention. However, around
one fifth of intervention patients did not attend any sessions,
with a majority of these not providing a reason for non-
attendance. Attendance at Group-MCT in the current study
was slightly lower than some previous studies, but comparisons
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are difficult to interpret because not all other studies report
attendance rates, and the studies are not within a cardiac sample.
Retention of participants in both trial groups was high. There
was some evidence for a higher—though still small—number of
participants randomized to Group-MCT formally withdrawing
from the study, but this was balanced by a greater rate of return
of follow-up questionnaires from this group. There appeared to
be no indication that attending Group-MCT led to a reduction in
attendance at CR sessions. It is important to note that reasons for
withdrawal from the study may have been influenced by the
format of delivery of the intervention. Some patients may not feel
comfortable attending a group intervention and may have
preferred a psychological intervention delivered on a one-to-
one basis.
The study had a high rate of return of follow-up questionnaires
with over 70% returned. The study used a broad range of strategies
to encourage returns including phone calls to check that patients
had received their follow-up questionnaire packs, reminder phone
calls asking patients to return them, and incentivizing return of
questionnaires. In addition, we also provided patients with a range
of options which included completing questionnaires over the
phone and face-to-face with a research assistant. While a range
of options were provided future studies should also consider
offering electronic data collection, which may help to increase
questionnaire return rates.
While the therapists reported a high level of adherence to the
manual we were unable to assess the quality of therapy delivered
throughout. This was due to limitations with audio recording
therapy sessions. In future, trials should not only assess
adherence to the manual but also quality of treatment delivery
via an independent rater.
On the basis of the results reported here extension of the
study to a full-scale trial was recommended. The results of the
feasibility study were reported to the trial steering committee and
the funder (NIHR), and the decision to extend recruitment to a
full-scale RCT was supported.
CONCLUSIONS
The implementation of psychological treatments for anxiety and
depression in physical health pathways presents several
challenges. Existing treatments have limited efficacy and are not
widely accessible. Furthermore, physical health care providers
typically lack the knowledge and experience necessary to deliver
complex psychological interventions. With these barriers in mind,
we evaluated the feasibility and acceptability of running a trial of
MCT in cardiac rehabilitation patients and delivered by non-
mental health specialist staff. Our feasibility study was
implemented as an internal pilot study, with the intention that
if findings were favorable the study would be extended by
continuing recruitment to a full-scale RCT.
The results suggest that a trial of MCT within the
rehabilitation pathway is feasible. The addition of MCT to
rehabilitation did not appear to have a negative impact on CR
retention. Most participants completed our a-priori definition of
a minimally effective dose of the intervention. Completion rates
of measures were good suggesting they did not over-burden
participants. The treatment approach also appeared feasible and
acceptable to health providers as we observed high levels of
therapist adherence to the protocol.
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11. Frasure-Smith N, Lespé rance F, Bentle M, Muhammad R. Depression and
Anxiety as Predictors of 2-Year Cardiac Events in Patients With Stable
Coronary Artery Disease. Arch Gen Psychiatry (2008) 65(1):62.
doi: 10.1001/archgenpsychiatry.2007.4
12. Sherwood A. Relationship of Depression to Death or Hospitalization in
Patients With Heart Failure. Arch Internal Med (2007) 167(4):367.
doi: 10.1001/archinte.167.4.367
13. Richards SH, Anderson L, Jenkinson CE, Whalley B, Rees K, Davies P,
et al. Psychological interventions for coronary heart disease. Cochrane
Database Systemat Rev (2018) 4:CD002902. doi: 10.1002/14651858.
CD002902.pub4
14. Dickens C, Cherrington A, Adeyemi I, Roughley K, Bower P, Garrett C, et al.
Characteristics of Psychological Interventions That Improve Depression in
People With Coronary Heart Disease: A Systematic Review and Meta-
Regression. Psychosomatic Med (2013) 75(2):211–21. doi: 10.1097/
PSY.0b013e31827ac009
15. Reavell J, Hopkinson M, Clarkesmith D, Lane DA. Effectiveness of Cognitive
Behavioural Therapy for Depression and Anxiety in Patients with
Cardiovascular Disease A Systematic Review and Meta-Analysis.
Psychosomatic Med (2018) 80(8):742–53. doi: 10.1097/PSY.0000000
000000626
16. Wells A. Metacognitive therapy for anxiety and depression. New York:
Guilford Press (2009).
17. Normann N, Morina N. The Efficacy of Metacognitive Therapy: A Systematic
Review and Meta-Analysis. Front Psychol (2018) 9:2211. doi: 10.3389/
fpsyg.2018.02211
18. Wells A, Matthews G. Attention and emotion: A clinical perspective. Hove:
Erlbaum (1994).
19. Wells A, Matthews G. Modelling Cognition in Emotional Disorder: The SREF
MODEL. Behav Res Ther (1996) 34(11):881–8. doi: 10.1016/S0005-7967(96)
00050-2
20. Papageorgiou C, Carlile K, Thorgaard S, Waring H, Haslam J, Horne L, et al.
Group Cognitive-Behavior Therapy or Group Metacognitive Therapy for
Obsessive-Compulsive Disorder? Benchmarking and Comparative
Effectiveness in a Routine Clinical Service. Front Psychol (2018) 9:2551.
doi: 10.3389/fpsyg.2018.02551
21. Rees CS, van Koesveld KE. An open trial of group metacognitive therapy for
obsessive-compulsive disorder. J Behav Ther Exp Psychiatry (2008) 39(4):451–
8. doi: 10.1016/j.jbtep.2007.11.004
22. Haseth S, Solem S, Sørø GB, Bjørnstad E, Grøtte T, Fisher P. Group
Metacognitive Therapy for Generalized Anxiety Disorder: A Pilot Feasibility
Trial. Front Psychol (2019) 10:290. doi: 10.3389/fpsyg.2019.00290
23. McEvoy PM, Erceg-Hurn DM, Anderson RA, Campbell BNC, Swan A,
Saulsman LM, et al. Group metacognitive therapy for repetitive negative
thinking in primary an non-primary generalized anxiety disorder: An
effectiveness trial. J Affect Disord (2015) 175(1):124–32. doi: 10.1016/
j.jad.2014.12.046
24. van der Heiden C, Melchior K, de Stigter E. The Effectiveness of Group
Metacognitive Therapy for Generalised Anxiety Disorder: A Pilot Study.
J Contemp Psychother (2013) 43:151–7. doi: 10.1007/s10879-013-9235-y
25. Papageorgiou C, Wells A. Group Metacognitive Therapy for Severe
Antidepressant and CBT Resistant Depression: A Baseline-Controlled Trial.
Cognit Ther Res (2015) 39:14–22. doi: 10.1007/s10608-014-9632-x
26. Dammen T, Papageorgiou C, Wells A. An open trial of group metacognitive
therapy for depression in Norway. Nordic J Psychiatry (2015) 69(2):126–31.
doi: 10.3109/08039488.2014.936502
27. Capobianco L, Reeves D, Morrison AP, Wells A. Group Metacognitive
Therapy vs. Mindfulness Meditation Therapy in a Transdiagnostic Patient
Sample: A Randomised Feasibility Trial. Psychiatry Res (2018) 250:554–61.
doi: 10.1016/j.psychres.2017.11.045
28. Callesen P, Capobianco L, Heal C, Juul C, Find Nielsen S, Wells A. A
Preliminary Evaluation of Transdiagnostic Group Metacognitive Therapy in
a Mixed Psychological Disorder Sample. Front Psychol (2019) 10:1341.
doi: 10.3389/fpsyg.2019.01341
29. Fisher PL, Byrne A, Fairburn L, Ullmer H, Abbey G, Salmon P. Brief
Metacognitive Therapy for Emotional Distress in Adult Cancer Survivors.
Front Psychol (2019). 10:162 doi: 10.3389/fpsyg.2019.00162
30. Fisher PL, Byrne A, Salmon P. Metacognitive therapy in adult survivors of
cancer: a case series. Cogn Ther Res (2017) 41:891–901. doi: 10.1007/s10608-
017-9862-9
31. Fisher PL, McNicol K, Young B, Smith E, Salmon P. An open trial of
metacognitive therapy for emotional distress in young adult survivors of
cancer. J Adolesc Young Adult Oncol (2015) 4:64–9. doi: 10.1089/jayao.
2014.0046
32. Wells A, McNicol K, Reeves D, Salmon P, Davies L, Heagerty A, et al.
Improving the effectiveness of psychological interventions for depression and
anxiety in the cardiac rehabilitation pathway using group-based metacognitive
therapy (PATHWAY Group MCT): study protocol for a randomised
controlled trial. Trials (2018) 19:215. doi: 10.1186/s13063-018-2593-8
33. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta
Psychiatr Scand (1983) 67(6):361–70. doi: 10.1111/j.1600-0447.1983.
tb09716.x
34. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thaban L, et al.
COSNORT 2010 statement: extension to randomised pilot and feasibility
trials. BMJ (2016) 355:i5239. doi: 10.1136/bmj.i5239
35. Hertzog MA. Considerations in determining sample size for pilot studies. Res
Nurs Health (2008) 31(2):180–91. doi: 10.1002/nur.20247
36. Greenberger D, Padesky C.Mind Over Mood: A Cognitive Therapy Treatment
Manual for Clients. New York: Guilford Press (1995).
37. Wells A. Group Metacognitive Therapy: Treatment Manual. Manchester, UK
(2015).
38. Martin CR, Lewin RJP, Thompson DR. A confirmatory factor analysis of the
Hospital Anxiety and Depression Scale in coronary care patients following
acute myocardial infarction. Psychiatry Res (2003) 120(1):85–94. doi: 10.1016/
S0165-1781(03)00162-8
39. Roberts SB, Bonnici DM, Mackinnon AJ, Worcester MC. Psychometric
evaluation of the Hospital Anxiety and Depression Scale (HADS) among
female cardiac patients. Br J Health Psychol (2001) 6(4):373–83. doi: 10.1348/
135910701169278
Wells et al. Feasibility Trial of Metacognitive Therapy
Frontiers in Psychiatry | www.frontiersin.org June 2020 | Volume 11 | Article 58210
40. Weiss DS, Marmar CR. The impact of event scale – revised. In: Wilson JP,
Keane TM, editors. Assessing psychological trauma and PTSD. New York:
Guilford Press (1997). p. 399–411.
41. Beck JG, DeMond GM, Read JP, Clapp JD, Coffey SF, Miller LM, et al. The
impact of event scale-revised: psychometric properties in a sample of motor
vehicle accident survivors. J Anxiety Disord (2008) 22(2):187–98. doi: 10.1016/
j.janxdis.2007.02.007
42. Creamer M, Bell R, Failla S. Psychometric properties of the impact of event
scale – revised. Behav Res Ther (2003) 41:1489–96. doi: 10.1016/
j.brat.2003.07.010
43. Wells A, Cartwright-Hatton S. A short form of the metacognitions
questionnaire: Properties of the MCQ-30. Behav Res Ther (2004) 42
(4):385–96. doi: 10.1016/S0005-7967(03)00147-5
44. Spada MM, Mohiyeddini C, Wells A. Measuring metacognitions associated
with emotional distress: factor structure and predictive validity of the
metacognitions questionnaire 30. Personal Individ Differ (2008) 45:238–42.
doi: 10.1016/j.paid.2008.04.005
45. Wells A. Cognitive Attentional Syndrome Scale 1 Revised (CAS-1R).
Manchester: University of Manchester (2015).
46. Faija C, Reeves D, Heal C, Capobianco L, Anderson R, Wells A. Measuring the
Cognitive Attentional Syndrome in Cardiac Patients with Anxiety and
Depression Symptoms: Psychometric Properties of the CAS-1R. Front
Psychol (2019) 10:2109. doi: 10.3389/fpsyg.2019.02109
47. EuroQol Group. EuroQol - a new facility for the measurement of health-
related quality of life. Health Policy (1990) 16(3):199–208. doi: 10.1016/0168-
8510(90)90421-9
48. Brooks R. EuroQol: The current state of play. Health Policy (1996) 37:53–72.
doi: 10.1016/0168-8510(96)00822-6
49. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining
meaningful change in psychotherapy research. J Consult Clin Psychol (1991)
59(1):12–9. doi: 10.1037//0022-006x.59.1.12
50. Liu Y, Pencheon E, Hunter RM, Moncrieff J, Freemantle N. Recruitment and
retention strategies in mental health trials- A systematic review. PloS One
(2018) 3(8):e0203127. doi: 10.1371/journal.pone.0203127
51. Turner A, Hambridge J, Baker A, Bowman J, McElduff P. Randomised
controlled trial of group cognitive behaviour therapy versus brief
intervention for depression in cardiac patients. Austrialian New Zelands J
Psychiatry (2012) 47(3):235–43. doi: 10.1177/0004867412460592
52. Sever S, Doherty P, Harrison AS, Golder S. To what extent is multi-morbidity
associatedwith new onset depression in patients attending cardiac rehabilitation?
BMC Cardiovasc Disord (2019) 19:256. doi: 10.1186/s12872-019-1245-6
Conflict of Interest: AW is the developer of metacognitive therapy and a co-
director of the Metacognitive Therapy Institute.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2020 Wells, Reeves, Heal, Fisher, Davies, Heagerty, Doherty and
Capobianco. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal is
cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Wells et al. Feasibility Trial of Metacognitive Therapy
Frontiers in Psychiatry | www.frontiersin.org June 2020 | Volume 11 | Article 58211
